Bromodomain-containing protein 4 (BRD4)

Overview

BRD4 (bromodomain-containing protein 4) is a member of the BET (bromodomain and extra-terminal domain) family of epigenetic reader proteins. It recognizes acetylated lysine residues on histones through its bromodomains and helps regulate chromatin-associated transcription, including RNA polymerase II–mediated gene expression. Because of this role, BRD4 is widely studied as a regulator of cell growth, survival, and oncogenic transcriptional programs.

In biomedical research, BRD4 is an important therapeutic target in cancer and other disease contexts where transcriptional control is dysregulated. Inhibition or degradation of BRD4 can suppress expression of tumor-driving genes, alter signaling pathways such as NF-κB signaling and Wnt/β-catenin pathway-related programs, and affect processes including proliferation, ferroptosis sensitivity, and viral latency-associated protein expression.

Recent Publications Summary

Recent studies continued to position Bromodomain-containing protein 4 (BRD4) as a therapeutic target across cancer and other disease models, with multiple approaches aimed at degrading or inhibiting its function. Several PROTAC-based strategies were reported, including a novel RIPK1-mediated degrader design platform (RIMTAC) that indirectly recruits VHL and produced potent, concentration- and time-dependent degradation of BRD4, AKT, and JAK1 in a UPS-dependent manner 42417401Jul. A separate study developed GID4-recruiting PROTACs, identifying compound a11 as a selective, GID4-dependent BRD4 degrader with strong activity in VHL- and CRBN-deficient models, superior antiproliferative effects in VHL-deficient 786-O renal cell carcinoma cells, and significant tumor growth inhibition in vivo 42402035Jul. Additional medicinal chemistry work generated diyne-bearing, low nanomolar BRD4 degraders recruiting CRBN, while also enabling Raman-based visualization of intracellular uptake 42094781May.

BRD4 was also explored in combination strategies and disease-specific contexts. In metastatic castration-resistant prostate cancer, dual BRD4/AKT inhibition was proposed to overcome c-MYC-driven resistance, and compound 21d was identified as a potent dual inhibitor with activity against both BRD4 and AKT1 41966583Apr. In pancreatic ductal adenocarcinoma, HDAC1/2 were shown to regulate H3K27ac distribution and maintain BRD4 and RNA polymerase II occupancy at DNA damage response gene promoters; HDAC inhibition with entinostat redistributed BRD4 away from promoters, suppressed DDR gene expression, and sensitized tumors to DNA-damaging and DDR-targeting agents 42348617Jun. A nanoparticle-based delivery system for entinostat was also developed to achieve tumor-selective HDAC inhibition with reduced systemic toxicity 42348617Jun.

Other reports linked BRD4 targeting to hematologic malignancy, viral infection, and fibrotic disease. In acute megakaryoblastic leukemia, BRD4 was investigated as a super-enhancer-associated therapeutic target, with the study focusing on BRD4 regulation of PIM1 as a novel vulnerability 42310709Jun. In KSHV-infected immortalized endothelial cells, BRD4 PROTAC degraders MZ-1 and SIM-1 inhibited cell growth by suppressing LANA translation through increased eIF2α phosphorylation 42224297Jun. In idiopathic pulmonary fibrosis, an inhalable polymeric PROTAC nanococktail was designed to degrade profibrotic signaling regulators in fibrotic lungs, illustrating the broader use of targeted protein degradation platforms in complex tissue disease 42341263Jun.

BRD4 was also used as a biochemical and analytical target in mechanistic and platform-development studies. A nanopore sensing approach enabled near-atomic discrimination of BRD4 interactions with histone peptides and diverse small-molecule drugs, including detection of BRD4-small-molecule complexes with subtle mass differences 42046448Apr. Finally, one study on 8-sulfonamidoquinoline derivatives noted that the parent scaffold had potent inhibitory activity against BRD4, although the optimized compound II-2 was advanced primarily as an antiproliferative agent in colorectal cancer and was mechanistically linked to NF-κB and Wnt/β-catenin signaling through binding to P65 41763019Feb.

What Changes, What Holds

1. BRD4 remains a tractable degradation target, but the new chemotypes mainly extend the toolkit rather than revise its biology
REINFORCES Multiple degrader platforms again support the established view of BRD4 as a druggable epigenetic reader whose function can be suppressed by targeted protein degradation. The added value is practical: indirect recruiter strategies, VHL-deficient activity, and imaging-enabled uptake readouts broaden how BRD4-directed agents may be built and evaluated, but they do not alter the baseline account of BRD4 as a therapeutic target in cancer and related settings. 42417401Jul42402035Jul42094781May

2. BRD4-linked combination therapy is being refined, not redefined
REINFORCES Dual BRD4/AKT inhibition and HDAC-dependent redistribution of BRD4 both fit the existing picture of BRD4 as a node in oncogenic transcriptional control that can be therapeutically exploited. What changes is the strategy: the new work suggests BRD4 may be most useful in combination regimens that reshape chromatin occupancy or bypass resistance pathways, especially in prostate and pancreatic cancer. The baseline role of BRD4 in transcriptional regulation and cancer remains intact. 41966583Apr42348617Jun

3. BRD4 targeting is expanding into disease-specific vulnerabilities, but the core therapeutic framing stays the same
REINFORCES The leukemia, KSHV, and fibrosis studies all keep BRD4 within the established therapeutic-degradation framework rather than assigning it a new biological class. They sharpen where BRD4 dependence matters, including super-enhancer-linked survival programs and viral protein expression, while the fibrosis nanococktail mainly illustrates a delivery platform for targeted degradation in tissue disease. None of this displaces the baseline view of BRD4 as a regulator of growth and survival programs. 42310709Jun42224297Jun42341263Jun

4. BRD4 is becoming a measurement standard as well as a drug target
METHOD The nanopore work changes how BRD4 interactions can be studied, enabling fine discrimination of protein-peptide and protein-small-molecule complexes rather than adding a new biological role. That makes BRD4 useful as a benchmark for analytical platforms that need to resolve subtle binding differences, but it leaves the established account of BRD4’s function and therapeutic relevance unchanged. The 8-sulfonamidoquinoline study also mainly reinforces BRD4 as a known inhibitory scaffold, even though its lead compound was pursued through other mechanisms. 42046448Apr41763019Feb

Overview update candidates: BRD4-targeted degradation platforms are now broad enough to mention as a major recent development; combination strategies that reposition BRD4 within resistance and chromatin-occupancy control may also merit inclusion.